News
-
-
PRESS RELEASE
Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
Sanofi gains EU approval for Cenrifki (tolebrutinib) as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses, based on phase 3 studies. Cenrifki addresses SPMS disability progression -
-
-
-
-
-
PRESS RELEASE
Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
Sanofi's Tzield receives US FDA approval as first disease-modifying therapy for stage 3 type 1 diabetes, targeting autoimmune attack against insulin-producing beta cells -
-
PRESS RELEASE
Press Release: Sanofi launches 2026 global employee stock purchase plan
Sanofi launches Action 2026 global employee stock purchase plan involving 75,000 employees in 52 countries. Employees offered discounted shares with free matching shares and limited purchase amount. Eligibility conditions and holding periods apply
